Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.54 |
| ▸ | BAD | Q92934 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | DRD3 | P35462 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31205278 | 0.98 | BCL2L1 (0.56) | BCL2L1BADL3MBTL1DRD2DRD3 | |
| SCHEMBL1339376 | 0.98 | BCL2L1 (0.56) | BCL2L1BADL3MBTL1DRD2DRD3 | |
| SCHEMBL30406611 | 0.93 | DRD2 (0.50) | BCL2L1BADL3MBTL1DRD2DRD3 | |
| SCHEMBL542749 | 0.93 | DRD2 (0.50) | BCL2L1BADL3MBTL1DRD2DRD3 | |
| SCHEMBL24011796 | 0.83 | — | — | |
| SCHEMBL30042165 | 0.83 | — | — | |
| Ammonia Solution, Strong SCHEMBL3977602 | 0.81 | DRD2 (0.52) | BCL2L1BADL3MBTL1DRD2DRD3 | |
| SCHEMBL16559380 | 0.76 | DRD2 (0.52) | DRD2DRD3TSHRADRA2A | |
| SCHEMBL31722376 | 0.75 | BCL2L1 (0.42) | BCL2L1BADL3MBTL1DRD2DRD3 | |
| SCHEMBL31011900 | 0.74 | BCL2L1 (0.56) | BCL2L1BADTSHRACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | BCL2L1 3/4885BAD 15/4885L3MBTL1 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.